BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

This study has been terminated.
Cancer International Research Group
Hoffmann-La Roche
Genentech, Inc.
Information provided by (Responsible Party):
NSABP Foundation Inc Identifier:
First received: February 21, 2008
Last updated: July 7, 2014
Last verified: July 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2014
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)